Rationale: Excess signaling through cardiac G␤␥ subunits is an important component of heart failure (HF) pathophysiology. They recruit elevated levels of cytosolic G protein-coupled receptor kinase (GRK)2 to agonist-stimulated ␤-adrenergic receptors (␤-ARs) in HF, leading to chronic ␤-AR desensitization and downregulation; these events are all hallmarks of HF. Previous data suggested that inhibiting G␤␥ signaling and its interaction with GRK2 could be of therapeutic value in HF. Objective: We sought to investigate small molecule G␤␥ inhibition in HF. Methods and Results: We recently described novel small molecule G␤␥ inhibitors that selectively block G␤␥-binding interactions, including M119 and its highly related analog, gallein. These compounds blocked interaction of G␤␥ and GRK2 in vitro and in HL60 cells. Here, we show they reduced ␤-AR-mediated membrane recruitment of GRK2 in isolated adult mouse cardiomyocytes. Furthermore, M119 enhanced both adenylyl cyclase activity and cardiomyocyte contractility in response to ␤-AR agonist. To evaluate their cardiac-specific effects in vivo, we initially used an acute pharmacological HF model (30 mg/kg per day isoproterenol, 7 days).
H eart failure (HF) is a devastating disease with poor prognosis, and remains a leading cause of death worldwide. 1, 2 Excess signaling through cardiac G protein G␤␥ subunits is an important component of HF pathophysiology. In particular, they recruit elevated levels of cytosolic G protein-coupled receptor kinase 2 (GRK2) (␤-adrenergic receptor kinase [␤-ARK]1) to agonist-stimulated ␤-ARs in HF, 3 leading to the chronic ␤-AR desensitization, downregulation and pathological signaling that are hallmarks of HF. 4, 5 Increasing evidence suggests a critical role for G␤␥mediated signaling in HF. In particular, GRK2 is significantly upregulated in cardiomyocytes of animal models of HF and human HF patients; this elevates G␤␥-GRK2 interactions and contributes to chronic desensitization of ␤-AR signaling 6,7 ; interestingly, levels of GRK2 appear to correlate with the severity of HF. 6, 8 Enhancing G␤␥-GRK2 interaction by cardiac targeted overexpression of GRK2(s) can directly cause HF in experimental animal models 9 ; its genetic ablation has generally proven to be cardioprotective. 10 -12 Several studies suggest targeting G␤␥-mediated signaling as an effective treatment for HF. First, studies using a G␤␥-sequestering peptide derived from the G␤␥-binding domain of GRK2, known as ␤ARKct or GRK2ct, have demonstrated that interfering with G␤␥ interactions in a variety of animal models of HF improves cardiac function, normalizes ␤-AR receptor levels and restores signaling responsiveness. 13, 14 Similarly, overexpression of a truncated dominant-negative form of phosducin, another G␤␥-binding protein, can also restore cardiac function when virally delivered to failing rabbit hearts. 15 Also, disruption of phosphatidylinositol 3-kinase (PI3K)␥ recruitment to the membraneassociated G␤␥-GRK2 complex by ␤ARKct or expression of the GRK2-binding PIK domain of PI3K␥ is cardioprotective in a variety of HF models. 16 -18 These large peptide inhibitor studies highlight the therapeutic potential of G␤␥ inhibitors in HF.
We recently developed a novel small molecule targeting strategy to selectively inhibit G␤␥-binding interactions. Studies from our laboratories have identified a number of small molecules that inhibit peptide binding to the protein interaction domain of the G␤␥ subunit, suggesting possible salutary modulation of pathological G␤␥-dependent signaling in HF. 19, 20 Here we demonstrate that 2 of these compounds, M119 and its highly related, similarly efficacious compound gallein, 19, 20 influence ␤-ARdependent, G␤␥-mediated signaling in isolated mouse cardiomyocytes. Furthermore, we show that these compounds block the progression of cardiac dysfunction and hypertrophy in 2 murine models of HF. We conclude that M119 and gallein, and other related G␤␥targeting compounds, will provide valuable tools for dissecting the functional importance of different G␤␥-protein interactions and may lead to development of G␤␥-targeted small molecule therapeutics for the treatment of HF. 32 12- week old C57Bl6-J wild-type male mice (The Jackson Laboratory) were divided into 4 groups of 8 mice each: V-V (isoproterenol [Iso] vehicle/M119 vehicle), V-M (Iso vehicle/M119), I-V (Iso/M119 vehicle), and I-M (Iso/M119). M119 or M119 vehicle (1ϫ PBS, pH 7.7) was delivered at 100 mg/kg per day via intraperitoneal injection (200 L/injection). Filtered solutions of Iso or Iso-vehicle (0.002% ascorbic acid in saline) were delivered via implantable miniosmotic pump at a concentration of 30 mg/kg per day. All animal procedures were performed in accordance with the guidelines of the Department of Laboratory Animal Medicine and the University Committee on Animal Resources at the University of Rochester Medical Center.
Methods

Animals
Isoproterenol Infusion
Calsequestrin
Ten 8-to 12-week-old CSQ overexpressing mice were divided into 2 groups: gallein and vehicle. Gallein or vehicle (1ϫ PBS, pH 7.7) was delivered at 30 mg/kg per day via daily peritoneal injection (200 L/injection). All animal procedures were performed in accordance with the guidelines of the Department of Laboratory Animal Medicine and the University Committee on Animal Resources at the University of Rochester Medical Center.
Echocardiography
Transthoracic 2D and M-mode echocardiography analysis was used to assess heart function in trained, conscious mice with a VisualSonics Vevo 770 echocardiography machine equipped with a 30MHz probe (VisualSonics). At least 5 animals from each group were measured and the pooled data were analyzed for statistical significance.
Myocyte Isolation
Wild-type male C57Bl6-J mice aged 12 to 16 weeks were anesthetized with 0.5 mL of heparin (100 U/mL) and 0.5 mL of ketamine/ midazolam in saline combination via intraperitoneal injection. Once anesthetized, the heart was removed, immediately suspended on a Langendorff apparatus by cannulation of the aortic root and perfused at constant rate of 4 mL/min at 37°C starting with 4 minutes of perfusion buffer (5 mmol/L NaHCO 3 , 30 mmol/L taurine, 10 mmol/L BDM, 5 mmol/L glucose, pH 7.4). Subsequently, enzymatic digestion was achieved by the infusion of calcium-free digestion buffer (120 mg collagenase type II in 50 mL perfusion buffer) for 3 minutes followed by 10 minutes of perfusion with calcium containing digestion buffer (digestion bufferϩ40 nmol/L CaCl 2 ). The heart was then removed and placed in a dish filled with 2 mL of stopping buffer (10% FBS, 12.5 mol/L CaCl 2 in perfusion buffer). Following removal of the atria, the ventricles were teased apart and pipetted into small pieces. To remove undigested tissue, the cell suspension was filtered through a 200-m mesh and allowed to settle by gravity for 10 minutes at 37°C. The supernatant was discarded and the cardiomyocyte pellet was resuspended in 10 mL of stopping buffer. CaCl 2 (100 mmol/L) was added incrementally to a final concentration of 1.2 mmol/L and the cardiomyocytes were again allowed to settle. The final pellet was resuspended in 5 mL of plating medium (MEM, 2.5% FBS, 1ϫ penicillin/streptomycin, 2 mmol/L L-glutamine) and plated onto laminin-coated BT-CS glass chamber slides (Cell Micro Controls) for 1 to 2 hours in a 37°C incubator at 2% CO 2 before contractility studies.
Myocyte Contractility
The glass chamber slides were placed on a microscope stage (Olympus IX71) connected to a field stimulator specifically designed for driving isolated cardiomyocytes (MyoPacer, IonOptix). Cardiomyocytes were stimulated at 0.5 Hz and imaged with a variable field-rate camera (MYO100 MyoCam, Ionoptix) using both edge detection and sarcomere length technology. Peak contraction was measured as the percentage of peak cell shortening. Cardiomyocytes were treated with one of 8 solutions: vehicle (control), Iso (1 mol/L), M119 (10 mol/L), gallein (10 mol/L), propranolol (1 mol/L), Iso/M119 (1 mol/L and 10 mol/L, respectively), propranolol/Iso (1 mol/L each), or propranolol/M119 (1 mol/L and 10 mol/L, respectively) for 10 minutes each. Treatment order was varied between experiments to control for time-dependent changes in cardiomyocyte contractility. All studies were recorded and saved in graphical and numeric formats. Each data point represents cardiomyocytes isolated from a different animal with at least 7 individual cardiomyocytes averaged per treatment and an equal number of contractions (Ͼ6) included for each cardiomyocyte.
Additional information and methods for morphometry/histology, protein preparation, immunoblotting, RNA extraction, real-time PCR, cAMP assay, statistical analysis, and small molecule information are all included in the expanded Methods section, available in the Online Data Supplement at http://circres.ahajournals.org.
Results
Small Molecule G␤␥ Inhibition Influences ␤-AR Signaling in Isolated Cardiomyocytes
We recently identified compounds M119 and gallein as highly related small molecules with similar efficacy that modulate GPCR signaling by interfering with G␤␥-binding interactions. M119 and gallein block peptide binding to G␤␥ with equal efficacy, they block G␤␥-GRK2 association in vitro and in HL-60 leukocytes in cell culture and produce equivalent dose-response curves in an inflammatory model in vivo (and Online Figure I ). 19, 20 Previous studies using peptide inhibitors of G␤␥ indicate that targeting of ␤-ARdependent, G␤␥-mediated signaling can lead to dramatic improvement in cardiac function in diverse models of HF. Here, we tested whether cell-permeant small molecules could influence ␤-AR signaling in cardiomyocytes and improve cardiac function in murine models of HF. To begin, we examined whether M119 affected basal and ␤-ARelicited cAMP generation in adult mouse cardiomyocytes. Elevation of cAMP production elicited by the ␤-AR agonist Iso was significantly enhanced in the presence of M119 ( Figure 1A) , which also induced a slight increase in cAMP at baseline. Next, we examined whether M119 or gallein influence ␤-AR-mediated GRK2 membrane recruitment. Adult mouse cardiomyocytes from wild type mice were pretreated with 10 mol/L gallein or vehicle followed by 1 mol/L Iso or vehicle, after which cardiomyocytes were subjected to subcellular fractionation. Immunoblot analysis of the membrane fraction demonstrated increased GRK2 with Iso alone compared to vehicle-treated cells ( Figure 1B The specificity of M119 on G␤␥ signaling was also determined by assessing electrophysiology in Xenopus oocytes expressing the cardiac G protein-coupled inward rectifying KACh channel (GIRK) subunits Kir3.1 and Kir3.4, together with the muscarinic type 2 receptor. M119 showed no affect on both the basal and ACh activated Kir3.1/Kir3.4 current (Online Figure III) , supporting previous data indicating these compounds selectively interfere with a subset of G␤␥ interactions.
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Based on these results, we sought to determine whether M119 could influence cardiomyocyte contractility both at baseline and in response to ␤-AR stimulation by measuring sarcomere shortening of isolated adult mouse cardiomyocytes. Compared to untreated cardiomyocytes, Iso significantly enhanced contractility demonstrating these cells were responsive to ␤-AR agonist (Figure 2A and 2B ). Combined treatment with Iso and M119 resulted in a further significant increase in contraction over Iso alone. In addition to affecting the length of sarcomere shortening, M119 alone and in combination with Iso also increased the rate of cardiomyocyte contraction ( Figure 2C ). The effect of M119 alone on cardiomyocyte contractility was not unexpected because M119 could enhance signaling downstream from constitutive signaling activity of ␤-ARs reported to account for a portion of baseline cardiomyocyte contractility. 21, 22 Consistent with previous reports of this phenomenon, we found that propranolol alone slightly reduced the rate of contraction ( Figure 2C ). Furthermore, we found that propranolol completely inhibited the effect of M119 (and Iso) on baseline contractility ( Figure  2B and 2C ), suggesting compound specificity for ␤-AR-G␤␥ signaling in cardiomyocytes. Collectively these data demonstrate that small molecule G␤␥ inhibition enhances ␤-ARmediated signaling and contractility in isolated adult cardiomyocytes. 
M119 Improves Cardiac Function in an Acute Pharmacological Model of HF
Based on our in vitro experiments, we next examined the effect of M119 on cardiac function in vivo. Chronic stimulation of ␤-ARs by Iso delivered via implantable miniosmotic pumps is an established acute pharmacological murine model of HF 12, 23 and this model was used to examine the effects of M119 on HF. Echocardiographic measurements were recorded from all mice before initiating the treatment regimen. Miniosmotic pumps containing Iso or saline were implanted and the mice were concurrently injected daily with M119 or vehicle for 7 days. Following 7 days of treatment, cardiac function was again analyzed by echocardiography. As shown in Figure 3 , Iso-treated mice showed significant signs of cardiac dysfunction after 7 days with a dramatic reduction in percent fractional shortening compared to vehicle controls. Mice treated with M119 alone showed no significant decrease in percent fractional shortening and no alteration in heart rate compared to vehicle controls, indicating that M119 by itself does not alter cardiac function (Figure 3 and Online Table I ). Importantly, Iso-treated mice that received daily injections of M119 maintained essentially normal contractile performance compared to significantly decreased cardiac function observed in Iso-pumped animals that received vehicle control injections (Figure 3 and Online Table I ). Iso-pumped animals treated with M119 also showed significant normalization of LV volumes and mean velocity of circumferential fiber shortening (Online Table I ).
Concurrent M119 Reduces Iso-Induced Cardiac Dysfunction and Hypertrophy
Cardiac morphometry was also examined to determine whether M119 influences hypertrophic growth of the heart. Following echocardiographic analysis of treated mice, body weight (BW) and heart weight (HW) were determined for all mice. As shown in Figure 3C , Iso-treated animals exhibited a Ϸ33% increase in mean HW:BW ratio compared to vehicle controls, indicating that chronic Iso infusion induced significant cardiac hypertrophy. By contrast, M119 treatment of Iso-pumped animals significantly reduced cardiac hypertrophy. These morphometric data were substantiated by significant normalization of ventricular wall thickness with M119 treatment of Iso-pumped animals as detected by echocardiography (Online Table I ). Animals treated with M119 alone showed no significant change in HW:BW ratio, indicating that this drug does not by itself induce cardiac hypertrophy.
Isolated hearts were examined using histological staining techniques. Hematoxylin and eosin staining revealed that hearts from Iso-pumped animals were visibly larger than vehicle-pumped animals, consistent with the observed effect on HW:BW ratios (data not shown). In addition, Masson's trichrome staining revealed that Iso-pumped, M119-treated animals demonstrate reduced interstitial and peri-vascular fibrosis compared to Iso-pumped animals ( Figure 3D ). No evidence of tissue pathology was found in any group on staining of lung, liver, or brain tissue (not shown).
Gallein Halts the Progression of HF in Mice With Established HF
Cardiac restricted calsequestrin overexpressing mice (CSQ) replicate many hallmarks of HF, including dysfunctional ␤-AR signaling. 24 To investigate the efficacy of G␤␥targeting compounds in halting HF progression, CSQ mice (a generous gift from Dr. Larry Jones) with established HF at 8 weeks of age were treated with the compound gallein, which is highly related and similarly efficacious to M119, 14 administered daily for 1 month by intraperitoneal injection. Echocardiographic analysis showed that gallein treatment completely prevented the progression of HF, maintaining essentially all echocardiographic measures, including functional data for both fractional shortening and ejection fraction (Figure 4 and Online Table II ). Conversely, vehicle-treated animals demonstrated progressive worsening of cardiac function and of numerous measures associated with the progression of eccentric hypertrophy and dilated cardiomyopathy, including chamber dilation and ventricular wall thinning (Figure 4 and Online Table II ). Additionally, morphometric analysis showed that gallein inhibited the progression of pathological cardiac hypertrophy associated with this genetic HF model ( Figure 5A and 5C ). Gallein also numerically (but not significantly) enhanced cardiac ␤-AR cell surface expression toward normal, determined by radioligand binding (Online Figure IV) . Finally, improved cardiac function in CSQ mice following gallein treatment was accompanied by a concomitant reduction in expression of both atrial natriuretic factor and ␤-myosin heavy chain ( Figure 5B ). In parallel experiments, age-, sex-, and background strain (DBA)-matched nontransgenic control animals received equivalent daily gallein or vehicle injections for one month. Compared to vehicle treatment, no histological abnormalities were observed in the gallein treated group (heart, lung, liver, brain; data not shown), nor were there any differences in cardiac morphology or morphometry (Online Figure V, B) . Interestingly, a slight but significant elevation of cardiac contractility (percentage fractional shortening) was observed by echocardiography in the gallein group following 1 month of treatment (Online Figure V, A; Online Table III) , mirroring prior reports that cardiac ␤ARKct expression slightly elevated cardiac contractility at baseline. 9, 25, 26 
Small Molecule G␤␥ Inhibitors Reduce GRK2 Expression in HF
Increased expression of GRK2 is a hallmark of HF; its reduction is concomitant with improved cardiac function. 6, 7, 27 Further, inducible ablation of cardiac GRK2 expression is cardioprotective. 10, 11 Therefore we examined whether small molecule G␤␥ inhibitor treatment altered cardiac GRK2 protein expression. As demonstrated previously, 23 Isopumped animals show robust increase in GRK2 protein level after one week of treatment ( Figure 6A ). Interestingly, upregulation of GRK2, indicative of HF, was significantly reduced in Iso-pumped animals treated with M119 ( Figure  6A ). GRK2 expression was also significantly decreased in CSQ animals treated with Gallein ( Figure 6B ). Thus, in addition to the immediate effects of small molecule G␤␥ inhibitor treatment on G␤␥-mediated GRK2 membrane recruitment demonstrated in cardiac myocytes in vitro, longterm small molecule G␤␥ inhibitor treatment normalized cardiac GRK2 expression in 2 distinct animal models of HF.
Discussion
Recent studies from our laboratories identified a number of small molecules that bind G␤␥ and modulate G␤␥-protein interactions. 19, 20 These compounds were able to inhibit a number of G␤␥-dependent signaling events, including G␤␥-GRK2 association. GRK2 protein levels are significantly elevated in HF, and substantial evidence indicates that blocking both G␤␥ and the GRK2-G␤␥ interaction in diverse HF models is cardioprotective. 13, 14 In this study, we tested whether M119 and its highly related and similarly efficacious G␤␥ compound inhibitor gallein could be used to target G␤␥ in cardiomyocytes and thereby influence aspects of ␤-AR signaling and improve cardiac function in animal models of HF. Our data indicate that M119 and gallein interfere with G␤␥-GRK2 interactions in cardiomyocytes, and may enhance ␤-AR signaling in vitro. M119 and gallein both halt HF progression and improve cardiac function, morphometry, histology and gene expression in animal models of either new onset or established HF.
Recruitment of GRK2 to the membrane by G␤␥ is among the more well-established functions of G␤␥ downstream of ␤-AR signaling. General inhibition of G␤␥, and of the G␤␥-GRK2 interaction, using various G␤␥ inhibitory peptides (eg, ␤ARKct, nt-del-Phosducin, PI3K␥ inact ) has proven to be a highly effective treatment for a variety of animal HF models and in isolated failing human cardiomyocytes. 28 The results of these studies have alternately been viewed as a specific effect of inhibiting GRK2 function and as a broader effect on G␤␥ signaling. Consistent with the latter hypothesis, another G␤␥ sequestering peptide, a truncated form of the G␤␥-binding protein phosducin (nt-del-Phosducin), has also been used successfully to restore ␤-AR signaling in cardiomyocytes. 29 More recently, a peptide inhibitor of PI3K␥, which is recruited to G␤␥ in part through association with GRK2, has also proven to be effective in treating animal models of HF. 16, 17, 27 Collectively these results suggest that generally inhibiting pathological G␤␥-dependent signaling in failing cardiomyocytes is salutary. Consistent with these observations, our novel small molecule based approach to targeting G␤␥ signaling appears to function, at least in part, like peptide inhibitors of G␤␥ signaling. Whether the observed effects are attributable specifically to G␤␥-GRK2 inhibition, or to other G␤␥ signaling components, will be a target of our future studies. Importantly, the present study suggests selective interference with a subset of G␤␥ interactions, as G␤␥-GIRK signaling was not affected (Online Figure III) .
Our studies of isolated adult cardiomyocytes showed that small molecule G␤␥ inhibition enhanced cAMP production and cardiomyocyte contractility following acute ␤-AR stimulation. These data are consistent with published results showing similar effects of ␤ARKct expression in cardiac myocytes in culture 28 and in vivo. 9 Because M119 and gallein were also found to reduce Iso-induced GRK2 membrane recruitment, we conclude that these small molecules influence ␤-AR signaling in cardiomyocytes similar to ␤ARKct.
G␤␥ inhibitory compounds M119 and gallein partially normalized cardiac morphology and gene expression and halted HF progression in the acute Iso pump model of HF and in CSQ mice with established HF. These data suggest promising utility of small molecule G␤␥ inhibition in treating both new onset and extant HF. Importantly, ␤-blockers are a standard therapy in the treatment of human HF. Combination of cardiac-restricted ␤ARKct expression with the ␤-blocker metoprolol has previously demonstrated synergistic benefit for cardiac function in CSQ mice, 30 suggesting a possible synergy of small molecule G␤␥ inhibition with ␤-blocker therapy, which will be a target of our future investigation.
In addition to its role in the cardiomyocytes, recent evidence demonstrates that dysregulation of AR-dependent G␤␥ signaling in other tissues may also contribute to cardiac dysfunction. Lymperopoulos et al recently showed a significant increase of GRK2 in the chromaffin cells of the adrenal medulla, suggesting that increased G␤␥-GRK2 association contributes to dysfunctional feedback inhibition of catecholamine release via ␣2-AR signaling. 31 Interestingly, viral delivery of ␤ARKct to the adrenal gland restored ␣ 2 -AR feedback inhibition of catecholamine release and dramatically improved cardiac function, attributable, at least in part, to decreased chronic stimulation of cardiac ␤-ARs. Increased GRK2 expression is also associated with hypertension. 32, 33 ␤-AR signaling normally promotes vasodilation but overexpression of GRK2 within vascular smooth muscle cells leads to diminished ␤-AR signaling and elevated resting blood pressure, a major risk factor for HF. 34 Because heart disease can result from dysfunctional signaling in multiple organs, we and others 31 believe that systemic delivery of small molecule G␤␥ inhibitors could simultaneously target multiple causes of this disease. This approach to modulating intracellular signaling is also consistent with the growing trend of therapeutics targeting intracellular components of pathological signaling in cardiovascular disease. 35 In summary, we have demonstrated that small molecule G␤␥ inhibitors function in vivo to improve cardiac function and halt HF progression in both new-onset and extant HF in mice. Small molecule G␤␥ inhibitors appear to maintain ␤-AR responsiveness, in part by interfering with GRK2 membrane recruitment. Future studies will determine whether G␤␥ inhibitor compounds modulate other known G␤␥dependent signaling events, including G␤␥-mediated signaling via novel extracellular signal-regulated kinase 1/2 phosphorylation 36 and whether these effects contribute to their effects in cardiac pathophysiology. Such studies will aim to determine whether small molecule targeting of G␤␥ may be an effective therapeutic paradigm for the treatment of HF.
